ClinTec ceo receives Honorary Doctorate

For her contribution to life sciences industry

Dr Rabinder Buttar has been awarded a Doctorate of the University (DUniv) by the University of the West of Scotland.

This honorary doctorate was awarded in recognition of Dr Buttar’s contribution to the life sciences Industry over 20 years and for the foundation and development of ClinTec International.

Professor Seamus McDaid, principal and vice chancellor of the University of the West of Scotland, said: ‘We are delighted to award Dr Buttar with an Honorary Doctorate. As chief executive of ClinTec International, she is one of the country’s most important business leaders, making a hugely important contribution to the Scottish economy.’

At the graduation ceremony, which took place in Paisley, Dr Buttar said: ‘The University has created an exceptional pool of local and international graduates and I am honoured to come back here after 20 years and accept this degree. These graduates here today have successfully completed one chapter of their lives and as they open the next one their learning should never stop.

‘In the current challenging times, graduates should seek local as well as global opportunities, look to do something they feel passionate about, be even more determined than ever before to succeed and then further success will be in their hands. The University and its excellent staff have prepared them well for the challenges that lie ahead.

‘I feel honoured and privileged to join the Court and Senate today in recognising and celebrating in some of Scotland’s academic achievements.’

Dr Buttar has also been named as the Ernst & Young Entrepreneur of the Year for Scotland and the Institute of Directors’ Regional Director of the Year for the West of Scotland.

You may also like

Research & Development

ClinTec expands into China, Singapore and Thailand

Increases presence in emerging markets
Finance

Pharmaceutical firms win Queen’s Awards for Enterprise

Eight firms are lauded for their success in innovation and international trade
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Finance

Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA

SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
Subscribe now